URLs : Tickets: Brochure: Time : 9:30 AM - 4:40 PM Prices : Drug Developer - Conference + Workshop Day: USD 4397.00, Academic - Conference + Workshop Day: USD 3797.00, Solution Provider - Conference + Workshop Day: USD 5397.00, Drug Developer - Conference Only: USD 3099.00, Academic - Conference Only: USD 2699.00, Solution Provider - Conference Only: USD 3899.00 Speakers : Alok Pachori, Medical Director, Global Development, AstraZeneca, Kristin Fiorino, Medical Director, AstraZeneca, Fady Botros, Associate Vice President, Cardiometabolic Health Clinical Research Design, Eli Lilly, Belle Van Rosmalen, Director, Medical Development, Eli Lilly, Maria Trujillo, Senior Director, Quantitative Pharmacology and Pharmacometrics, Merck, Allison Goldfine, Executive Director, Translational Medicine, Cardiovascular and Metabolism, Novartis BioMedical Research, Rosemarie Sellati, Senior Director, Global Patient Advocacy, Regeneron, Adriana Ramos, Principal Scientist and Head of Lab, Sanofi, Bryan Jones, Chief Operating Officer, Aardvark Therapeutics, Steffen-Sebastian Bolz, Co-Founder, Executive Board Member and Chief Scientific Officer, Aphaia Pharma, Dr
It can be taken at any time of day, independent of meals
Efficacy and tolerability of vildagliptin monotherapy drug-naive patients with type 2 diabetes
Lactic acidosis portends a poor prognosis (by Kings College Hospital (KCH) criteria), and the mechanism of lactic acidemia is two-fold: NAPQI being present in excess and causing mitochondrial dysregulation, followed in subsequent hours by tissue hypoxia and decreased hepatic metabolism and clearance of lactate, leading to a two-hit effect on worsening of the lactic acidosis condition
